RLRebecca Landy

Rebecca Landy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rebecca Landy has a total of 310 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late‐stage incidence end points and post‐trial ongoing evaluation—The Peachtree Consensus

    by Ruth Etzioni, Larry Kessler, Deb Schrag, Peter Sasieni, Hilary A. Robbins, Hormuzd A. Katki, Stephen W. Duffy, Roman Gulati, Diana Buist, Sean Tunis, et al.

    Background: In a new era of multicancer early detection (MCED), late‐stage incidence has been proposed as an end point for the evaluation of test efficacy, marking a departure from the established end point of cancer mortality. Methods: The American Cancer Society convened a panel of 15 academic researchers with expertise in cancer screening evaluation to develop principles assuring the validity and interpretability of MCED trials with late‐stage incidence end points and advancing implementation of tests with potential for meaningful clinical utility. Results: The definition of late‐stage cancer is critical and affects study design, interpretation, and outcomes. The authors of the Peachtree Consensus recommend considering cancer‐type–specific definitions of late stage and paying attention to comparability of staging intensity in both trial arms. The duration of screening and the follow‐up interval after the last screen should be chosen based on the preclinical early stage and late‐stage durations of the target cancer types. The authors also recommend reporting aggregate results and results for individual cancer types as numbers permit and summarizing relative and absolute benefits. Predicted mortality reductions should be calculated to contextualize a late‐stage result and the inputs and assumptions involved should be reported. Given a significant late‐stage reduction suggestive of meaningful clinical benefit, the authors support launching consortium and demonstration studies while continuing to track trial mortality outcomes. Conclusions: Trials with late‐stage incidence end points that are conducted using these principles should support the development of evidence‐based screening guidelines as well as the creation of accessible data resources for observational and modeling studies.


  • Open Access

    Using a mobile unit to deliver capsule sponge testing for Barrett’s oesophagus in the community in England through GP invitation and self-referral: an implementation study

    by Rebecca Landy, Jo Waller, Irene Debiram-Beecham, Abigail Kerridge, James Booth, Peter Holloway, James Morrow, Fiona M Walter, Mimi McCord, Peter D Sasieni, et al.

    Objective: Offering individuals with gastro-oesophageal reflux a non-endoscopic capsule sponge test increased detection of Barrett’s oesophagus (BO), a precursor to oesophageal adenocarcinoma. However, only 24% of individuals identified through general practitioner (GP) records participated. We therefore performed an implementation study to assess the feasibility of screening on a mobile unit and screening uptake among GP-invited and self-referred individuals. Methods: In this implementation study, 3293 individuals aged ≥50 with a repeat proton pump inhibitor prescription were invited to participate by their GPs across three GP practices in the East of England between June 2021 and January 2023. Additionally, we advertised the study and allowed self-referrals. Eligibility was assessed based on age and reflux history. Eligible individuals were invited to an appointment. Acceptability was assessed after the appointment. Individuals with a positive capsule sponge test were referred for endoscopy. Results: Half of the GP-invited individuals responded, of whom 59.6% (n=952/1598) were interested. Among interested individuals who could be contacted, 66.3% (n=574/866) were eligible, and 532 participated. Of these, 502 (94%) successfully swallowed a capsule sponge, representing 15% of those invited and 87.5% of eligible individuals. Among 468 individuals who self-referred and could be contacted, 48.5% (n=227) were eligible, 217 participated, and 208 (96%) successfully swallowed a capsule sponge (39.6% of self-referred, 91.6% of eligible individuals). 9.4% (n=47/502) of GP-invited and 12.0% (n=25/208) of self-referred individuals were referred for endoscopy, with 4.2% (n=21/502) and 3.4% (n=7/208), respectively, diagnosed with BO (positive predictive value of endoscopy referral=42.4%), including three with dysplasia. Over 99% of participants said the capsule sponge test was acceptable. Conclusion: Screening on a mobile unit is feasible. Identifying individuals at increased risk of BO from GP records is feasible, and encouraging self-referrals increases uptake. BO prevalence was similar among eligible participants who self-referred and those identified through GP records. Trial registration number: ISRCTN91655550 .


  • Open Access

    A natural history model of oesophageal adenocarcinoma to inform power calculations for the BEST4 screening trial

    by Rebecca Landy, John W Correira, Rebecca C Fitzgerald, Peter D Sasieni

    Objective: Oesophageal adenocarcinoma (OAC) has a poor prognosis, often due to its late stage at diagnosis. Individuals diagnosed with Barrett's oesophagus (BO), a precursor condition to OAC, are offered surveillance with the goal of identifying and treating dysplastic BO, preventing progression to cancer. The BEST4 Screening randomised controlled trial was designed to demonstrate a reduction in (i) incidence of stage II + or fatal OAC and (ii) OAC mortality through targeted capsule sponge screening in high-risk individuals. Here we describe the simple natural history model we developed to inform the sample size calculation for the BEST4 screening trial. Methods: We considered a range of annual transition probabilities between states to evaluate the impact on the incidence of (i) stage II + or fatal OAC and (ii) OAC mortality, and therefore the statistical power to identify a reduction in each of these endpoints. We additionally considered a range of baseline prevalences for each state, as well as for screening uptake, capsule sponge sensitivity and treatment efficacy. Results: Under the assumptions considered, the BEST4 trial will have >90% power to detect a difference in incidence of stage II + or fatal OAC by 5.5 years, and mortality by 7.5 years, under most parameter combinations, and by 8.5 years and 12 years, respectively, under all combinations. The model is freely available to download. Conclusion: A simple semi-Markov natural history model can be used to explore the power of a clinical trial with group-sequential analysis under a wide range of scenarios regarding the natural history of disease.

  • Risk-Based Prophylactic Human Papillomavirus Vaccination of Heterosexual US Men Aged 27 to 45 Years for Prevention of Oropharyngeal Cancer

    by Anil K Chaturvedi, Gregory W Haber, Barry I Graubard, Li C Cheung, Maura L Gillison, Rebecca Landy

    Human papillomavirus (HPV) vaccination of US individuals aged 27–45 years is recommended through shared clinical decision-making. To enable shared decision-making, we used a microsimulation-based state-transition model to develop and validate a risk-prediction model to identify heterosexual men aged 27–45 years at high-risk of acquiring oral HPV-16 infections. A risk model for incident oral HPV-16 infections had good discrimination (AUC = 0.73) and calibration (ratio of expected to the observed number of incident oral HPV-16 infections through age 45 years [E/O] = 1.01) in internal cross-validation. Compared to vaccinating all men aged 27–45, vaccinating 44% of men with highest model-predicted risk would prevent 80% of incident oral HPV-16 infections through age 45 years and reduce the number needed to be vaccinated to prevent 1 infection by 45% (184 vs 100).


  • Open Access

    Individual- and Group-Level Disparities Between Racial and Ethnic Groups in Lung Cancer Screening Eligibility Criteria

    by Corey D. Young, Hormuzd A. Katki, Li C. Cheung, M. Patricia Rivera, Hilary A. Robbins, Melinda C. Aldrich, Jeffrey D. Blume, Anil K. Chaturvedi, Rebecca Landy

    Importance: Lung cancer screening guidelines result in differential screening eligibility among individuals who might benefit equally from screening and in population-level differences in screening eligibility and benefit across races and ethnicities.Objective: To inform lung cancer screening policy development by evaluating how enforcing (1) equal lung cancer screening eligibility for all individuals with equal benefit and (2) equal program sensitivity across racial and ethnic subgroups are associated with screening eligibility and benefit.Design, Setting, and Participants: This cross-sectional comparative effectiveness study included 6915 members of the US noninstitutionalized population aged 50 to 80 years who ever smoked and who participated in the 2015 National Health Interview Survey. Statistical analysis was performed from May 2022 to April 2024.Exposure: Lung cancer screening eligibility is based on the LYFS-CT (life-years gained from screening–computed tomography) prediction model, which predicts gain in life expectancy from screening, where individuals are eligible if their predicted benefit exceeds a threshold across all possible thresholds.Main Outcomes and Measures: The proportion of individuals aged 50 to 80 years who ever smoked who are eligible for screening, the percentage of predicted gainable life gained from screening (program sensitivity), and the number needed to screen to gain 10 years of life (screening efficiency), by race and ethnicity.Results: The 6915 participants aged 50 to 80 years who ever smoked represented 44 million individuals (mean age, 63 years [IQR, 56-69 years]; 53% male; 68% formerly smoked; 10% African American individuals, 3% Asian American individuals, 8% Hispanic American individuals, and 79% non-Hispanic White individuals). To ensure equal screening eligibility for each race and ethnicity required race- and ethnicity-specific eligibility thresholds. To achieve 36% eligibility for each race and ethnicity, the required days of life gained (under the LYFS-CT model) screening eligibility thresholds would be 5.2 for Hispanic American individuals, 5.6 for Asian American individuals, 9.5 for non-Hispanic White indivduals, and 12.4 for African American individuals, so individuals of different races and ethnicities with the same benefit would have different eligibility. With a fixed eligibility threshold of 16.2 days, screening eligibility would differ across races and ethnicities; 7% of Hispanic American individuals, 9% of Asian American individuals, 20% of non-Hispanic White individuals, and 27% of African American individuals aged 50 to 80 years who ever smoked would be eligible for screening. Similar differences existed for the program sensitivity of screening benefit. African American individuals consistently maintained the most efficient number needed to screen across all thresholds; Hispanic American individuals had the least efficient number needed to screen and thus may experience the worst benefit-harm balance when equalizing program sensitivity between races and ethnicities.Conclusions and Relevance: This comparative effectiveness study of lung cancer screening eligibility suggests that screening eligibility criteria cannot result in both equal eligibility for all individuals with the same benefit and equal program sensitivity for each race and ethnicity. In general, race- and ethnicity-specific thresholds that result in equal group-level sensitivity on 1 metric cannot result in equal sensitivities on other metrics. Thus, only 1 metric can be equalized, requiring a value judgment on which to prioritize.


  • Impact of screening for human papillomavirus-positive oropharyngeal cancers: a microsimulation-based modeling study

    by Rebecca Landy, Gregory W Haber, Barry I Graubard, Carole Fakhry, Nicole G Campos, Emily A Burger, Li C Cheung, Hormuzd A Katki, Maura L Gillison, Anil K Chaturvedi

    Background: We estimated the impact of screening on morbidity and mortality of human papillomavirus (HPV)16-positive oropharyngeal cancer among US men aged 45-79 years. Methods: We developed an individual-level, state-transition natural history microsimulation model to estimate the impact of screening using oral HPV16 detection, HPV16-E6 antibody detection, and transcervical ultrasound of neck/oropharynx. We compared clinical detection to counterfactual screen detection for cancer stage, single- vs multiple-modality treatment, and survival. Screening scenarios encompassed 4 progression speeds across cancer stages (very slow, slow, fast, and very fast) and 4 screening frequencies. Results: Among US men aged 45-79 years in 2021 (n = 54 881 311), 163 958 clinically diagnosed human papillomavirus (HPV)-positive oropharyngeal cancers and 32 009 deaths would occur through age 84 in the absence of screening. Assuming very-fast progression, 4%, 20%, 31%, and 60% of these cancers would be detected by one-off, 5-yearly, 3-yearly, and annual screening. Annual screening (very-fast progression) could reduce the number of cancers diagnosed at advanced stages (American Joint Committee on Cancer, 7th edition, stages III/IV: 90.0% with no screening vs 59.1%) and treated by multiple modalities (80.6% with no screening vs 50.6%). Cancer mortality would also be reduced by 36.2%, with a gain of 106 000 life-years. Annual screening would have a number needed to screen (NNS) of 561 per screen-detected cancer, 1118 per additional cancer treated by single modality, 4740 per death prevented, and 520 per life-year gained; such high NNS reflect potential inefficiency of population-level screening. Conclusions: If proven efficacious in randomized trials and cost-effective, screening for HPV-positive oropharyngeal cancers could provide considerable population-level reductions in advanced stage cancers, treatment-related morbidities, and mortality.


  • The Development and Performance of Alternative Criteria for Lung Cancer Screening

    by Lauren E. Kearney, Patrick Belancourt, Hormuzd A. Katki, Nichole T. Tanner, Renda Soylemez Wiener, Hilary A. Robbins, Rebecca Landy, Tanner J. Caverly

    The recommendation for lung cancer screening (LCS) developed by the U.S. Preventive Services Task Force (USPSTF) may exclude some high-benefit people. To determine whether alternative criteria can identify these high-benefit people. Model-based projections. United States. People from the 1997-2014 National Health Interview Survey (NHIS) to develop alternative criteria using fast-and-frugal tree algorithms and from the 2014-2018 NHIS and the 2022 Behavioral Risk Factor Surveillance System for comparisons of USPSTF criteria versus alternative criteria. Life-years gained from LCS were estimated using the life-years gained from screening computed tomography (LYFS-CT) model. "High-benefit" was defined as gaining an average of at least 16.2 days of life from 3 annual screenings, which reflects high lung cancer risk and substantial life gains if lung cancer is detected by screening. The final alternative criteria were 1) people who smoked any amount each year for at least 40 years, or 2) people aged 60 to 80 years with at least 40 pack-years of smoking. The USPSTF and alternative criteria selected similar numbers of people for LCS. Compared with the USPSTF criteria, the alternative criteria had higher sensitivity (91% vs. 78%; P < 0.001) and specificity (86% vs. 84%; P < 0.001) for identifying high-benefit people. For racial and ethnic minorities, the alternative criteria provided greater gains in sensitivity than the USPSTF criteria (Black: 83% vs. 56% [P < 0.001]; Hispanic: 95% vs. 73% [P = 0.086]; Asian: 94% vs. 68% [P = 0.171]) at similar specificity. The alternative criteria identify high-risk, high-benefit groups excluded by the USPSTF criteria (those with a smoking duration of ≥40 years but 15 years), many of whom are members of racial and ethnic minorities. The results were based on model projections. These results suggest that simple alternative LCS criteria can identify substantially more high-benefit people, especially in some racial and ethnic groups. U.S. Department of Veterans Affairs Lung Precision Oncology Program.


  • Open Access

    The risk and benefit profiles of US-eligible lung cancer screening attendees vs nonattendees

    by Elizabeth Y Zhang, Li C Cheung, Hormuzd A Katki, Barry I Graubard, Ahmedin Jemal, Anil K Chaturvedi, Rebecca Landy

    Background: The US Preventive Services Task Force (USPSTF) recommend lung cancer screening for individuals aged 50-80 years with at least 20 pack-years and no more than 15 quit-years, but uptake is low. The risk and benefit profiles of screening attendees are unknown; consequently, the impact and lost opportunity of ongoing lung cancer screening in the United States remains unclear. Methods: We estimated lung cancer death risk (using the Lung Cancer Death Risk Assessment Tool) and life gained from screening (using the Life Years Gained From Screening-Computed Tomography model) for individuals aged 50-79 years who ever-smoked in the US representative 2022 Behavioral Risk Factor Surveillance System. We compared lung cancer death risk and life gained among USPSTF-eligible individuals by screening status (self-reported screened vs not screened in past year) and estimated the number of lung cancer deaths averted and life-years gained under current screening levels and if everyone eligible was screened. Results: USPSTF eligibility was 33.7% (95% confidence interval [CI] = 33.1% to 34.4%), of whom 17.9% (95% CI = 17.0% to 18.8%) self-reported screening. Screening uptake increased with increasing lung cancer death risk quintile (Q1 = 5.2%, 95% CI = 3.0% to 8.8%; Q5 = 21.8%, 95% CI = 20.3% to 23.3%) and life-gain from screening quintile (Q1 = 6.2%, 95% CI = 3.8% to 9.9%; Q5 = 20.8%, 95% CI = 19.5% to 22.2%). Screened individuals had higher lung cancer death risk (risk ratio [RR] = 1.35, 95% CI = 1.26 to 1.46) and life-years gained (RR = 1.19, 95% CI = 1.12 to 1.25) than unscreened individuals. Currently, screening averts 19 306 lung cancer deaths and gains 237 564 life-years; screening everyone eligible would additionally avert 56 956 lung cancer deaths and gain 751 850 life-years. Two-thirds of USPSTF lung-eligible women were up to date with breast cancer screening, but only 17.3% attended lung screening in the past year. Conclusions: Eligible screening attendees had higher lung cancer death risk and benefit from screening. Higher rates of screening could substantially increase the number of lung cancer deaths prevented.


  • Open Access

    Risk of COVID‐19 death for people with a pre‐existing cancer diagnosis prior to COVID‐19‐vaccination: A systematic review and meta‐analysis

    by Julia Steinberg, Suzanne Hughes, Harriet Hui, Matthew J. Allsop, Sam Egger, Michael David, Michael Caruana, Peter Coxeter, Chelsea Carle, Tonia Onyeka, et al.

    While previous reviews found a positive association between pre‐existing cancer diagnosis and COVID‐19‐related death, most early studies did not distinguish long‐term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher‐quality evidence on risk of COVID‐19‐related death for people with recent/active cancer (compared to people without) in the pre‐COVID‐19‐vaccination period. We searched the WHO COVID‐19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk‐of‐bias assessment was based on the Newcastle‐Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse‐variance random‐effects models. Random‐effects meta‐regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID‐19‐related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36‐1.61, I2 = 0; people with COVID‐19: aOR = 1.58, 95% CI: 1.41‐1.77, I2 = 0.58; inpatients with COVID‐19: aOR = 1.66, 95% CI: 1.34‐2.06, I2 = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4‐4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68‐2.68, I2 = 0.43), and for metastatic cancers. Meta‐regression suggested risk of COVID‐19‐related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37‐1.75) at 1 year and aOR = 0.98 (95% CI: 0.80‐1.20) at 5 years post‐cancer diagnosis/treatment. In conclusion, before COVID‐19‐vaccination, risk of COVID‐19‐related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis/treatment.


  • Open Access

    Absolute lung cancer risk increases among individuals with >15 quit‐years: Analyses to inform the update of the American Cancer Society lung cancer screening guidelines

    by Rebecca Landy, Li C. Cheung, Corey D. Young, Anil K. Chaturvedi, Hormuzd A. Katki

    Background: This report quantifies counteracting effects of quit‐years and concomitant aging on lung cancer risk, especially on exceeding 15 quit‐years, when the US Preventive Services Task Force (USPSTF) recommends curtailing lung‐cancer screening.Methods: Cox models were fitted to estimate absolute lung cancer risk among Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and National Lung Screening Trial (NLST) participants who ever smoked. Absolute lung cancer risk and gainable years of life from screening for individuals aged 50 to 80 in the US‐representative National Health Interview Survey (NHIS) 2015–2018 who ever smoked were projected. Relaxing USPSTF recommendations to 20/25/30 quit‐years versus augmenting USPSTF criteria with individuals whose estimated gain in life expectancy from screening exceeded 16.2 days according to the Life Years From Screening‐CT (LYFS‐CT) prediction model was compared.Results: Absolute lung cancer risk increased by 8.7%/year (95% CI, 7.7%–9.7%; p < .001) as individuals aged beyond 15 quit‐years in the PLCO, with similar results in NHIS and NLST. For example, mean 5‐year lung cancer risk for those aged 65 years with 15 quit‐years = 1.47% (95% CI, 1.35%–1.59%) versus 1.76% (95% CI, 1.62%–1.90%) for those aged 70 years with 20 quit‐years in the PLCO. Removing the quit‐year criterion would make 4.9 million more people eligible and increase the proportion of preventable lung cancer deaths prevented (sensitivity) from 63.7% to 74.2%. Alternatively, augmentation using LYFS‐CT would make 1.7 million more people eligible while increasing the lung cancer death sensitivity to 74.0%.Conclusions: Because of aging, absolute lung cancer risk increases beyond 15 quit‐years, which does not support exemption from screening or curtailing screening once it has been initiated. Compared with relaxing the USPSTF quit‐year criterion, augmentation using LYFS‐CT could prevent most of the deaths at substantially superior efficiency, while also preventing deaths among individuals who currently smoke with low intensity or long duration.